Statin use and survival after colorectal cancer: The importance of comprehensive confounder adjustment

Journal of the National Cancer Institute

Volumn 107, Issue 6, 2015, Pages

  Hoffmeister, Michael ^a   Jansen, Lina ^a   Rudolph, Anja ^b   Toth, Csaba ^c   Kloor, Matthias ^d   Roth, Wilfried ^a,c   Bläker, Hendrik ^e   Chang Claude, Jenny ^b   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Division of Cancer Epidemiology   (Germany)

^c Department of Pathology ^*  (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FOLLOW UP; GERMANY; HEART DISEASE; HEART PROTECTION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; SENSITIVITY ANALYSIS; TREATMENT DURATION; CANCER STAGING; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84930714534     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv045     Document Type: Article

References (40)

1. Sleijfer S, van der Gaast A, Planting AS, et al. The potential of statins as part of anti-cancer treatment. Eur J Cancer. 2005;41(4):516-522.
2. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer. 2005;5(12):930-942.
3. Kodach LL, Bleuming SA, Peppelenbosch MP, et al. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology. 2007;133(4):1272-1281.
4. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal cancer: A colonoscopy-controlled case-control study. BMC Gastroenterol. 2012;12:36.
5. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: A series of nested case-control studies. BMC Cancer. 2011;11:409.
6. Lee JE, Baba Y, Ng K, et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila). 2011;4(11):1808-1815.
7. Cheng MH, Chiu HF, Ho SC, et al. Statin use and the risk of colorectal cancer: A population-based case-control study. World J Gastroenterol. 2011;17(47):5197-5202.
8. Hachem C, Morgan R, Johnson M, et al. Statins and the risk of colorectal carcinoma: A nested case-control study in veterans with diabetes. Am J Gastroenterol. 2009;104(5):1241-1248.
9. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: A prospective cohort study. Drugs. 2009;69(11):1445-1457.
10. Yang YX, Hennessy S, Propert K, et al. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf. 2008;17(9):869-876.
11. Xiao H, Yang CS. Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention. Int J Cancer. 2008;123(5):983-990.
12. Boudreau DM, Koehler E, Rulyak SJ, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3076-3080.
13. Vinogradova Y, Hippisley-Cox J, Coupland C, et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology. 2007;133(2):393-402.
14. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115(1):27-33.
15. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: A population-based casecontrol study. Int J Cancer. 2007;121(6):1325-1330.
16. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst. 2007;99(1):32-40.
17. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007;18(2):213-219.
18. Bonovas S, Filioussi K, Flordellis CS, et al. Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007;25(23):3462-3468.
19. Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006;98(1):69-72.
20. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-2192.
21. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut. 2010;59(11):1572-1585.
22. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancerrelated mortality. N Engl J Med. 2012;367(19):1792-1802.
23. Caporaso NE. Statins and cancer-related mortality-let's work together. N Engl J Med. 2012;367(19):1848-1850.
24. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after colorectal cancer diagnosis and survival: A population-based cohort study. J Clin Oncol. 2014;32(28):3177-3183.
25. Brenner H, Chang-Claude J, Jansen L, et al. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014;146(3):709-717.
26. Jansen L, Hoffmeister M, Arndt V, et al. Stage-specific associations between beta blocker use and prognosis after colorectal cancer. Cancer. 2014;120(8):1178-1186.
27. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2013. Oslo 2012.
28. Jansen L, Below J, Chang-Claude J, et al. Beta blocker use and colorectal cancer risk: population-based case-control study. Cancer. 2012;118(16):3911-3919.
29. Hoffmeister M, Blaker H, Kloor M, et al. Body mass index and microsatellite instability in colorectal cancer: A population-based study. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2303-2311.
30. Findeisen P, Kloor M, Merx S, et al. T25 repeat in the 3' untranslated region of the CASP2 gene: A sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res. 2005;65(18):8072-8078.
31. Blaker H, Helmchen B, Bonisch A, et al. Mutational activation of the RASRAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol. 2004;39(8):748-753.
32. Warth A, Kloor M, Schirmacher P, et al. Genetics and epigenetics of small bowel adenocarcinoma: The interactions of CIN, MSI, and CIMP. Mod Pathol. 2011;24(4):564-570.
33. Rudolph A, Toth C, Hoffmeister M, et al. Expression of oestrogen receptor beta and prognosis of colorectal cancer. Br J Cancer. 2012;107(5):831-839.
34. Siddiqui AA, Nazario H, Mahgoub A, et al. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci. 2009;54(6):1307-1311.
35. Lakha F, Theodoratou E, Farrington SM, et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer. 2012;12(1):487.
36. Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011;103(20):1540-1551.
37. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
38. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422-1431.
39. Bulbulia R, Armitage J. Does the benefit from statin therapy extend beyond 5 years? Curr Atheroscler Rep. 2013;15(2):297.
40. National Surgical Adjuvant Breast and Bowel Project Foundation. Statin Polyp Prevention Trial in Patients With Resected Colon Cancer. http://clinicaltrials. gov/show/NCT01011478. Accessed October 30, 2014.